Characteristics of infective endocarditis in a cancer population.
Catheters, Indwelling
/ adverse effects
Echocardiography
/ methods
Endocarditis
/ diagnosis
Female
Follow-Up Studies
Humans
Immunocompromised Host
Incidence
Male
Middle Aged
Neoplasms
/ complications
Retrospective Studies
Risk Factors
Staphylococcal Infections
/ diagnosis
Staphylococcus aureus
/ isolation & purification
Survival Rate
/ trends
Tertiary Care Centers
Texas
/ epidemiology
endocarditis
epidemiology
infection
Journal
Open heart
ISSN: 2053-3624
Titre abrégé: Open Heart
Pays: England
ID NLM: 101631219
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
23
03
2021
accepted:
13
07
2021
entrez:
4
8
2021
pubmed:
5
8
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Infective endocarditis (IE) is more common in patients with cancer as compared with the general population. Due to an immunocompromised state, the need for invasive procedures, hypercoagulability and the presence of indwelling catheters, patients with cancer are particularly predisposed to the development of IE. Limited information exists about IE in patients with cancer. We aimed to evaluate the characteristics of patients with cancer and IE at our tertiary care centre, including a comparison of the microorganisms implicated and their association with mortality. A retrospective chart review of patients with cancer who had echocardiography for suspicion of endocarditis was conducted. A total of 56 patients with a confirmed diagnosis of cancer and endocarditis, based on the modified Duke criteria, were included in the study. Baseline demographics, risk factors for developing IE, echocardiography findings, microbiology and mortality data were analysed. Following the findings of vegetations by echocardiography, the median survival time was 8.5 months. Overall survival of patients with cancer and endocarditis is poor, with a worse outcome in patients with SAE.
Sections du résumé
BACKGROUND
Infective endocarditis (IE) is more common in patients with cancer as compared with the general population. Due to an immunocompromised state, the need for invasive procedures, hypercoagulability and the presence of indwelling catheters, patients with cancer are particularly predisposed to the development of IE.
OBJECTIVES
Limited information exists about IE in patients with cancer. We aimed to evaluate the characteristics of patients with cancer and IE at our tertiary care centre, including a comparison of the microorganisms implicated and their association with mortality.
METHODS
A retrospective chart review of patients with cancer who had echocardiography for suspicion of endocarditis was conducted. A total of 56 patients with a confirmed diagnosis of cancer and endocarditis, based on the modified Duke criteria, were included in the study. Baseline demographics, risk factors for developing IE, echocardiography findings, microbiology and mortality data were analysed.
RESULTS
Following the findings of vegetations by echocardiography, the median survival time was 8.5 months.
CONCLUSIONS
Overall survival of patients with cancer and endocarditis is poor, with a worse outcome in patients with SAE.
Identifiants
pubmed: 34344722
pii: openhrt-2021-001664
doi: 10.1136/openhrt-2021-001664
pmc: PMC8336187
pii:
doi:
Types de publication
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Mayo Clin Proc. 2010 May;85(5):422-6
pubmed: 20435834
J Am Coll Cardiol. 2016 Jan 19;67(2):151-158
pubmed: 26791061
Antimicrob Agents Chemother. 2002 Oct;46(10):3268-72
pubmed: 12234857
Am J Surg. 2011 Jul;202(1):10-5
pubmed: 21601826
Medicine (Baltimore). 2006 Mar;85(2):86-94
pubmed: 16609347
Heart. 2001 May;85(5):590-3
pubmed: 11303018
Thromb Res. 2007;120 Suppl 2:S51-61
pubmed: 18023713
J Clin Med. 2020 Jul 14;9(7):
pubmed: 32674517
Am J Infect Control. 2011 May;39(4 Suppl 1):S1-34
pubmed: 21511081
Am J Med. 1994 Mar;96(3):200-9
pubmed: 8154507
Am Heart J. 2019 Sep;215:70-77
pubmed: 31299559
Circulation. 2010 Jan 26;121(3):458-77
pubmed: 20048212
Int J Antimicrob Agents. 2019 Jan;53(1):9-15
pubmed: 30240836
Medicine (Baltimore). 2017 Sep;96(38):e7913
pubmed: 28930826
Clin Microbiol Rev. 2016 Apr;29(2):201-22
pubmed: 26817630
J Clin Oncol. 2013 Apr 1;31(10):1357-70
pubmed: 23460705
Ann Intern Med. 1970 Mar;72(3):341-8
pubmed: 4984425
Arch Intern Med. 1995 Jun 12;155(11):1177-84
pubmed: 7763123
Medicine (Baltimore). 2016 Mar;95(12):e3198
pubmed: 27015220
Eur Heart J. 2003 Jul;24(13):1231-43
pubmed: 12831818
J Vasc Interv Radiol. 2016 Mar;27(3):339-43; quiz 344
pubmed: 26776446
Ann Thorac Surg. 2019 Nov;108(5):1325-1329
pubmed: 31103387
Circ Arrhythm Electrophysiol. 2009 Feb;2(1):29-34
pubmed: 19808441
J Vasc Interv Radiol. 2012 Mar;23(3):358-62
pubmed: 22365295
In Vivo. 2019 Sep-Oct;33(5):1565-1572
pubmed: 31471406
Eur J Cardiothorac Surg. 2007 Nov;32(5):696-701
pubmed: 17881239
Radiology. 2019 May;291(2):513-518
pubmed: 30747596
N Engl J Med. 2013 Jun 13;368(24):2255-65
pubmed: 23718152
Clin Infect Dis. 2000 Apr;30(4):633-8
pubmed: 10770721
Arch Intern Med. 2009 Mar 9;169(5):463-73
pubmed: 19273776
Int J Med Microbiol. 2018 Aug;308(6):640-652
pubmed: 29526448
Expert Rev Anti Infect Ther. 2015;13(12):1499-516
pubmed: 26646248
Circulation. 2015 Oct 13;132(15):1435-86
pubmed: 26373316
Circ J. 2019 Jan 25;83(2):452-460
pubmed: 30555101
Eur J Epidemiol. 2016 Jan;31(1):41-9
pubmed: 26683995
Surg Oncol. 2011 Mar;20(1):20-5
pubmed: 19819688
Oncologist. 2007 May;12(5):518-23
pubmed: 17522239
J Am Coll Cardiol. 2018 Jun 19;71(24):2744-2752
pubmed: 29903348
Clin Infect Dis. 2012 May;54(9):1230-9
pubmed: 22492317
Clin Infect Dis. 2004 Aug 1;39(3):309-17
pubmed: 15306996
Clin Infect Dis. 2010 Jul 15;51(2):131-40
pubmed: 20540619
J Clin Microbiol. 1991 Oct;29(10):2245-9
pubmed: 1939578
Am J Surg. 2010 Dec;200(6):719-22; disussion 722-3
pubmed: 21146010
Clin Microbiol Infect. 2006 Mar;12(3):217-23
pubmed: 16451407
Lancet. 2016 Feb 27;387(10021):882-93
pubmed: 26341945
Clin Infect Dis. 2005 Mar 1;40(5):695-703
pubmed: 15714415
JAMA. 2005 Jun 22;293(24):3012-21
pubmed: 15972563
Medicine (Baltimore). 2017 Nov;96(47):e8392
pubmed: 29381916
Enferm Infecc Microbiol Clin (Engl Ed). 2018 Feb;36(2):72-77
pubmed: 27986340